|Articles|July 1, 1998

July 1998
Volume 4
Issue 7

Treatment Options for Prostate Cancer: Part 1--Stage, Grade, PSA, and Changes in the 1990's

Author(s)LTC Judd W. Moul, MD, MC, USA

Download PDF: Treatment Options for Prostate Cancer: Part 1--Stage, Grade, PSA, and Changes in the 1990's

Articles in this issue

about 28 years ago

Article

A New Method of Developing Expert Consensus Practice Guidelines

about 28 years ago

Article

Patient Consultation in a Managed Care Setting: Guiding Pharmacy into the Future

about 28 years ago

Article

Should Clinicians Rely on Expert Opinion or Empirical Findings?

about 28 years ago

Article

Compliance with Anti-Hypertensive Therapy: Raising the Bar of Expectations

about 28 years ago

Article

In Vitro and Skin Testing for Allergy: Comparable Clinical Utility and Costs

about 28 years ago

Article

Impact of Pharmacist Consultations Provided to Patients with Diabetes on Healthcare Costs in a Health Maintenance Organization

about 28 years ago

Article

The Cost-Effectiveness of Treatment with Lamivudine and Zidovudine Compared with Zidovudine Alone: A Comparison of Markov Model and Trial Data Estimates

about 28 years ago

Article

Introducing Managed Care to the Medical School Curriculum: Effect on Student Attitudes

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Treatment Options for Prostate Cancer: Part 1--Stage, Grade, PSA, and Changes in the 1990's

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access